Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Mikkael A. Sekeres, Maria Diez-Campelo, Amer M. Zeidan, Uwe Platzbecker, Antoine Regnault, Kristin Creel, Nishan Sengupta, Ying Wan, Libo Sun, Qi Xia, Tymara Berry, Souria Dougherty, Sheetal Shah, Shyamala Navada, Valeria Santini, David Valcárcel

Blood (2023) 142 (Supplement 1): 6479.

https://doi.org/10.1182/blood-2023-181103

Published: 2023

Journal Articles

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Blood (2022) 140 (Supplement 1): 1106–1108.

https://doi.org/10.1182/blood-2022-169050

Published: 2022

Journal Articles

MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis

Terrence Bradley, Andrew Kuykendall, Rami S. Komrokji, Tymara Berry, Souria Dougherty, Laurie Sherman, Lixian Peng, Fei Huang, Ying Wan, Faye Feller, John Mascarenhas

Blood (2022) 140 (Supplement 1): 3941–3942.

https://doi.org/10.1182/blood-2022-159614

Published: 2022

Journal Articles

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

John Mascarenhas, Claire Harrison, Jean-Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro M. Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 6826–6829.

https://doi.org/10.1182/blood-2022-160364

Published: 2022

Journal Articles

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Blood (2021) 138 (Supplement 1): 2598.

https://doi.org/10.1182/blood-2021-148876

Published: 2021

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)

John Mascarenhas, Claire N. Harrison, Jean-Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Vannucchi, Tymara Berry, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Aleksandra Rizo, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 1503.

https://doi.org/10.1182/blood-2021-148931

Published: 2021

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Rami S. Komrokji, MD, Steffen Koschmieder, MD, Alessandro M. Vannucchi, MD, Tymara Berry, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Libo Sun, PhD, Fei Huang, PhD, Ying Wan, PhD, Faye Feller, MD, Aleksandra Rizo, MD PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138915

Published: 2020

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Tymara Berry, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138818

Published: 2020

Journal Articles

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Tymara Berry, MD, Faye Feller, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138905

Published: 2020

Journal Articles

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Fei Huang, PhD, Aleksandra Rizo, MD PhD, Libo Sun, PhD, Ying Wan, PhD, Alessandro M. Vannucchi, MD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138823

Published: 2020

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, MD, Bruno Martino, MD, Dietger Niederwieser, MD, Andreas Reiter, MD, Bart L Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Jacqueline Bussolari, PhD, Eugene Zhu, PhD, Fei Huang, PhD, Esther Rose, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye M. Feller, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 685.

https://doi.org/10.1182/blood-2018-99-115163

Published: 2018

NARROW

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only